首页|分析阿司匹林联合硫酸氢氯吡格雷口服治疗脑梗死的有效性

分析阿司匹林联合硫酸氢氯吡格雷口服治疗脑梗死的有效性

扫码查看
目的 探究阿司匹林联合硫酸氢氯吡格雷口服治疗脑梗死的有效性.方法 240 例脑梗死患者,参考双盲法原则分为观察组和对照组,各 120 例.对照组患者采取阿司匹林口服治疗,观察组患者采取阿司匹林联合硫酸氢氯吡格雷口服治疗.对比两组治疗效果、活化部分凝血酶原时间、凝血酶原时间、凝血酶时间、纤维蛋白原、血小板聚集率、美国国立卫生研究院卒中量表(NIHSS)评分及Barthel指数、不良反应发生率.结果 观察组、对照组临床总有效率分别为 98.33%、85.00%,观察组临床治疗总有效率较对照组更高(P<0.05).治疗后,观察组纤维蛋白原(2.41±0.43)g/L水平较对照组的(3.85±0.64)g/L更低(P<0.05);观察组活化部分凝血酶原时间、凝血酶原时间、凝血酶时间分别为(35.48±2.21)、(13.19±1.53)、(20.45±2.24)s,均较对照组的(30.47±2.15)、(10.83±1.27)、(16.75±1.87)s更长(P<0.05).两组治疗前血小板聚集率对比无明显差异(P>0.05);治疗 2、4 周后,两组血小板聚集率均明显下降,且观察组血小板聚集率(33.22±4.47)%、(37.13±4.26)%较对照组的(40.78±4.75)%、(43.67±4.39)%更低(P<0.05).两组治疗前NIHSS评分及Barthel指数对比无明显差异(P>0.05);治疗后,两组NIHSS评分均下降,Barthel指数均上升,且NIHSS评分(10.23±1.04)分、Barthel指数(72.53±5.46)分较对照组的(17.72±1.28)、(60.78±4.35)分更优(P<0.05).治疗后,观察组、对照组不良反应发生率分别为 3.33%、14.17%,观察组不良反应发生率较对照组低(P<0.05).结论 针对脑梗死患者采取阿司匹林联合硫酸氢氯吡格雷口服治疗能够显著增强临床疗效,降低血小板聚集率,改善患者凝血指标、神经功能及日常活动能力,并有效减少不良反应发生.
Analysis of the effectiveness of aspirin combined with clopidogrel bisulfate in the treatment of cerebral infarction
Objective To explore the effectiveness of aspirin combined with clopidogrel bisulfate in the treatment of cerebral infarction.Methods 240 patients with cerebral infarction were divided into an observation group and a control group according to the principle of double-blind method,each with 120 cases.Patients in the control group were treated with aspirin orally,and patients in the observation group were treated with aspirin combined with clopidogrel bisulfate orally.Comparison was made on treatment effect,activated partial prothrombin time,prothrombin time,thrombin time,fibrinogen,platelet aggregation rate,National Institutes of Health Stroke Scale(NIHSS)score and Barthel index,and the incidence of adverse reactions between the two groups.Results The total clinical effective rate of the observation group and the control group were 98.33%and 85.00%,and the total clinical effective rate of the observation group was at a higher level(P<0.05).After treatment,the level of fibrinogen of(2.41±0.43)g/L in the observation group was lower than(3.85±0.64)g/L in the control group(P<0.05).The activated partial prothrombin time,prothrombin time and thrombin time in the observation group were(35.48±2.21),(13.19±1.53)and(20.45±2.24)s,which were longer than(30.47±2.15),(10.83±1.27)and(16.75±1.87)s in the control group(P<0.05).Before treatment,there was no significant difference in platelet aggregation rate between the two groups(P>0.05).After 2 and 4 weeks of treatment,the platelet aggregation rate decreased significantly in both groups;the platelet aggregation rate in the observation group were(33.22±4.47)%and(37.13±4.26)%,which were lower than(40.78±4.75)%and(43.67±4.39)%in the control group(P<0.05).Before treatment,there were no significant differences in NIHSS score and Barthel index between the two groups(P>0.05).After treatment,the NIHSS score of both groups decreased,and the Barthel index score increased significantly;NIHSS score and Barthel index score were(10.23±1.04)and(72.53±5.46)points,which were better than(17.72±1.28)and(60.78±4.35)points of the control group(P<0.05).After different treatment regimens,the incidence of adverse reactions in the observation group and the control group were 3.33%and 14.17%,and the incidence of adverse reactions in the observation group was lower(P<0.05).Conclusion Oral administration of aspirin and clopidogrel bisulfate in patients with cerebral infarction can significantly enhance the clinical efficacy,reduce the platelet aggregation rate,improve the patients'coagulation index,neurological function and daily activities,and effectively reduce the occurrence of adverse reactions.

Cerebral infarctionAspirinClopidogrel bisulfateClinical effect

孙莎莎、杜晓红、李香

展开 >

261500 高密市人民医院

脑梗死 阿司匹林 硫酸氢氯吡格雷 临床效果

2024

中国实用医药
中国康复医学会

中国实用医药

影响因子:0.797
ISSN:1673-7555
年,卷(期):2024.19(18)